Letrozole or tamoxifen in early breast cancer [1]

New England Journal of Medicine

Volumn 354, Issue 14, 2006, Pages 1528-

  Buzdar, Aman U ^a,d   Baum, Michael ^b   Cuzick, Jack ^c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d ATAC Steering Committee ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; LETROZOLE; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; NITRILE; TRIAZOLE DERIVATIVE; AROMATASE INHIBITOR;

BREAST CANCER; CARDIOVASCULAR RISK; CLINICAL TRIAL; DEATH; HEART INFARCTION; HUMAN; LETTER; MEDICAL RESEARCH; PRIORITY JOURNAL; SIDE EFFECT; BREAST TUMOR; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; MORTALITY; NOTE; ADJUVANT CHEMOTHERAPY; STATISTICAL ANALYSIS; LYMPH NODE METASTASIS; RECURRENT DISEASE;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; HUMANS; NITRILES; TAMOXIFEN; TRIAZOLES; AROMATASE INHIBITORS; CHEMOTHERAPY, ADJUVANT; DATA INTERPRETATION, STATISTICAL; LYMPHATIC METASTASIS; RECURRENCE;

EID: 33645503063     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc060194     Document Type: Letter

References (4)

1. The Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353:2747-57.
2. ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:60-2.
3. Cuzick J. Forest plots and the interpretation of subgroups. Lancet 2005;365:1308.
4. Howell A. ATAC trial update. Lancet 2005;365:1225-6.